Market Place
Sourcing Support
Daiichi Sankyo`s Ifinatamab Deruxtecan Gets Priority Review
14 Apr 2026 //
PHARMIWEB
Imagene AI Daiichi Sankyo Partner To Advance Oncology Biomarker
09 Apr 2026 //
PHARMIWEB
Leveragen, Daiichi Sankyo Partner on In Vivo Antibody Platforms
18 Mar 2026 //
PHARMIWEB
Daiichi Sankyo, AZ`s Enhertu wins US priority review
09 Mar 2026 //
FIERCE PHARMA
Daiichi pens Pact for High Cholesterol Digital Therapeutic
05 Mar 2026 //
FIERCE BIOTECH
Sylamorebio Collab With Daiichi On Sylec Delivery Technology
23 Feb 2026 //
PHARMIWEB
OX40, Roche-Sanegene, Daiichi—Fierce Pharma Asia
06 Feb 2026 //
FIERCE PHARMA
DS3790 Enters Clinic as First DXd ADC in Hematology by Daiichi
04 Feb 2026 //
BUSINESSWIRE
FDA Priority Review for DATROWAY for Metastatic Breast Cancer
03 Feb 2026 //
BUSINESSWIRE
Daiichi Stops Internal Development Of Next-Wave ADC
02 Feb 2026 //
FIERCE BIOTECH
Daiichi Sankyo Navigates Complexity Of Success
26 Jan 2026 //
FIERCE PHARMA
ENHERTU + Pertuzumab EU Filing Validated for HER2+ Breast Cancer
19 Jan 2026 //
BUSINESSWIRE
ENHERTU Plus Pertuzumab EU Type II Variation Validated
19 Jan 2026 //
BUSINESSWIRE
FDA Lifts Hold On Merck, Daiichi`s Lung Cancer ADC Trial
13 Jan 2026 //
BIOSPACE
Daiichi to Boost Production with $1.9B in Investments
05 Jan 2026 //
FIERCE PHARMA
ENHERTU Launches Adjuvant Phase 3 Trial in HER2+ Endometrial
22 Dec 2025 //
BUSINESSWIRE
FDA Grants ENHERTU BTD for HER2+ Early Breast Cancer
22 Dec 2025 //
BUSINESSWIRE
FDA OKs ENHERTU Breakthrough Designation for HER2+ Breast Cancer
22 Dec 2025 //
BUSINESSWIRE
EU Validates DATROWAY for First-Line Metastatic Treatment
18 Dec 2025 //
BUSINESSWIRE
Daiichi-Merck Ph. 3 ADC Program On Pause After Patient Deaths
18 Dec 2025 //
FIERCE BIOTECH
FDA Approves AZ/Daiichi`s Enhertu in 1st-Line Breast Cancer
15 Dec 2025 //
BUSINESSWIRE
DESTINY-Ovarian01—ENHERTU Phase 3 Begins for HER2+Ovarian Cancer
09 Dec 2025 //
BUSINESSWIRE
Daiichi Sankyo Highlights ADC Portfolio In Breast Cancer Trials
08 Dec 2025 //
BUSINESSWIRE
Daiichi Prevails On Appeal In ADC Patent Battle With Seagen
04 Dec 2025 //
FIERCE PHARMA
Daiichi Sankyo Initiates First Human Trial For Cancer Therapy
14 Nov 2025 //
INDPHARMAPOST
General Proximity, Daiichi Sankyo Team on Novel OmniTAC Platform
12 Nov 2025 //
PR NEWSWIRE
DS3610 Enters Clinical Development for Advanced Solid Tumors
10 Nov 2025 //
BUSINESS WIRE
Destiny-Lung06 Trial Begins: Enhertu Phase 3 For 1St-Line HER2
30 Oct 2025 //
BUSINESSWIRE
ESMO: Daiichi, Merck Move Ovarian Cancer ADC Toward Pivotal Test
20 Oct 2025 //
FIERCE BIOTECH
Datroway Shows 5-Month Survival Gain Over Chemotherapy
19 Oct 2025 //
BUSINESSWIRE
DS-3939 Shows Promising Activity in Advanced Solid Tumors
19 Oct 2025 //
BUSINESSWIRE
ESMO: Datroway Data Edge Out Trodelvy In First TROP2 Face-Off
19 Oct 2025 //
FIERCE PHARMA
Enhertu+THP Yields 67% pCR in High-Risk HER2+ Breast Cancer
18 Oct 2025 //
BUSINESSWIRE
Enhertu Cuts Recurrence or Death Risk by 53% in Ph3 Breast Trial
18 Oct 2025 //
BUSINESSWIRE
ENHERTU® Preceded By THP Yields 67% Pathologic Response
18 Oct 2025 //
BUSINESSWIRE
Enhertu Cuts Recurrence Risk By 53% In High-Risk Her2 Cancer
18 Oct 2025 //
BUSINESSWIRE
ESMO: Enhertu Wields 2-Fisted Power In Early Breast Cancer
18 Oct 2025 //
FIERCE PHARMA
ESMO: Astrazeneca Data `Validate` Focus On In-House Adcs
18 Oct 2025 //
FIERCE BIOTECH
Datroway`s Rilvegostomig Show Promise Result in Urothelial Cancer
17 Oct 2025 //
BUSINESSWIRE
Daiichi Sankyo Advances Breast Cancer Care With Landmark Trials
13 Oct 2025 //
BUSINESSWIRE
ENHERTU THP Combo BLA Accepted for High-Risk HER2+ Breast Cancer
01 Oct 2025 //
BUSINESSWIRE
ENHERTU Shows iDFS Benefit in High-Risk Early Breast Cancer
29 Sep 2025 //
BUSINESSWIRE
Az, Daiichi`s Enhertu Notches Another Win In Early Breast Cancer
29 Sep 2025 //
FIERCE PHARMA
Enhertu And Pertuzumab Priority Review For Her2+ Breast Cancer
24 Sep 2025 //
BUSINESSWIRE
ENHERTU + Pertuzumab Gets US Priority Review In 1L HER2+ Cancer
24 Sep 2025 //
BUSINESSWIRE
Immuto Scientific Secures $8M Seed 2 Funding, Collaborates
18 Sep 2025 //
PHARMAWEB
FDA Grants BTD To R-DXd For Platinum-Resistant Ovarian Cancers
16 Sep 2025 //
INDPHARMAPOST
FDA Grants Breakthrough Tag to Raludotatug Deruxtecan in CDH6
15 Sep 2025 //
BUSINESSWIRE
ENHERTU Type II Variation Validated in EU for HER2 Solid Tumors
11 Sep 2025 //
BUSINESSWIRE
Daiichi, Merck Prepare for Swift Approval Filing
07 Sep 2025 //
FIERCE BIOTECH
Daiichi Sankyo`s Ifinatamab Deruxtecan Shows Promising Response
07 Sep 2025 //
BUSINESSWIRE
HERTHENA-Breast04 Ph3 Starts for Patritumab Deruxtecan in Cancer
27 Aug 2025 //
BUSINESSWIRE
Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation
18 Aug 2025 //
CONTRACTPHARMA
Ifinatamab Deruxtecan Gets FDA BTD for ES-SCLC Patients
18 Aug 2025 //
BUSINESSWIRE
Daiichi Sankyo Presents ADC Data, SCLC Updates at WCLC 2025
14 Aug 2025 //
BUSINESSWIRE
Enhertu + Pertuzumab Get US BTD for HER2+ Breast Cancer
17 Jul 2025 //
BUSINESSWIRE
Datroway approved in US as first TROP2 Therapy for Lung Cancer
23 Jun 2025 //
BUSINESSWIRE
IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Begins
18 Jun 2025 //
BUSINESSWIRE
Enhertu+Pertuzumab Cuts Risk 44% in HER2+ Breast Ca Ph3
02 Jun 2025 //
BUSINESSWIRE
Enhertu Reduces Death Risk by 30% vs Ramucirumab Plus Paclitaxel
31 May 2025 //
BUSINESSWIRE
